Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April...
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April...
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on...
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif.,...
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine...
Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the BoardROSELAND,...
· Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to...
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies...
-- Prescription Drug User Fee Act (PDUFA) target date of October 2026 -- -- Submission supported by CESSA Phase 3...
Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN),...
LONDON, April 21, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced the presentation of new insights from its Phase 1/2...
DENVER, April 21, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report...
- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one...
USPTO Validates Catheter Precision’s LockeT Technology with Key Patent Allowance, Reinforcing Competitive Dominance, Long-Term Value Creation and Strengthening Barriers to...
New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with...
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting...
Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review...
Expanding into AI, Tokenization, Private Markets and the Emerging R3EQ Equity Token Ecosystem BOSTON, MA, April 21, 2026 (GLOBE NEWSWIRE)...